Platform Portfolio
Medfiniti currently operates through HemWell MD while maintaining a platform structure designed to support disciplined future expansion.
HemWell MD
HemWell MD Gen 2 launched in February 2025 with enhanced device architecture and improved connectivity. Rollout is underway across 65+ existing clinical centers nationwide, replacing Gen 1. Gen 1 (launched 2023) has performed 15,500+ cumulative procedures. Gen 2 uses patented low-voltage direct current (DC) electrolysis to coagulate tissue without thermal damage, offering a differentiated, FDA-cleared approach to hemorrhoidal disease treatment.
- FDA-cleared treatment for grades I–IV hemorrhoidal disease
- Gen 2 launch (February 2025) with enhanced device architecture and connectivity
- Performed in surgical facilities with minimal pain and rapid recovery profile
- Superior device economics versus competing treatment alternatives — materially lowering barriers to physician adoption
- Recurring revenue model driven by per-procedure utilization and consumables
HemWell MD outperforms traditional treatments across all key metrics.
A clinical and economic comparison against the most common alternatives in hemorrhoidal disease treatment.
| Metric | HemWell MD | Rubber Band Ligation | Surgery |
|---|---|---|---|
| Pain | Minimal | Severe | High |
| Recovery | Immediate | 2+ weeks | 4–6 weeks |
| Success Rate | 90–100% efficacy* | 60–70% | 85% |
| Grades Treated | I–IV (all grades) | I–II only | I–IV |
| Thermal Risk | None (non-thermal) | Low | High |
*90–100% efficacy based on pooled pilot studies and case series; RCT data pending.
Sources: ACG Guidelines 2024, pooled case series data from leading hemorrhoid treatment centers. Competitor success rates: Traditional ligation 60–70%, Sclerotherapy 85%, Laser 80–85% per ACG Guidelines.
What physicians are saying
"The patients are enthusiastic about the painless ease of the treatments and the fact that we can perform the whole procedure in minutes."
"This method allowed me to treat all grades of hemorrhoids painlessly. In my hands, I achieved close to a 100% success rate."
"The comfort level with using the device rose quickly, after seeing the relief that my patients were getting."
"I have treated over 4,000 patients using the Gen 1 device, and have not had a single complication. Patient satisfaction is over 95%."
Real outcomes, real lives improved
"I would tell anyone suffering, don't wait, this treatment is truly amazing and it is life altering. Thanks to HemWell MD I have my life back and feel amazing."
"It was true what they said about painless and quick. Right after the treatment, I went right back to work, literally right after the treatment. The treatment eliminated my hemorrhoids completely and I no longer suffer."
"It was very quick and I went back to taking care of my little ones as soon as I got home. I haven't had any symptoms since then, and it's been years."
Platform Expansion
Medfiniti is structured to support disciplined expansion into additional clinical applications where strategically appropriate. Future growth may occur through internal development, regulatory expansion, or selective acquisition without requiring new platform infrastructure.
- Disciplined evaluation of adjacent clinical applications
- Shared infrastructure can support future expansion
- Regulatory and commercial pathways assessed case by case
- No requirement to rebuild core operating architecture
Building HIPAA-compliant procedural data capture to create real-time clinical insights, evidence-based protocol optimization, and AI-ready infrastructure for future platform expansion.
Enhanced device architectures expanding procedural capability and clinical scope across indications.
Evaluation of non-GI clinical applications where the platform technology and economic model may apply.
